Tralesinidase Alfa (TA-ERT)
Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
Phase 3Investigational, active development
Key Facts
Indication
Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
Phase
Phase 3
Status
Investigational, active development
Company
About Spruce Biosciences
Spruce Biosciences is a public, clinical-stage biotech focused on rare neurological and endocrine disorders, with its lead asset, TA-ERT, in Phase 3 for MPS IIIB. The company operates with a patient-inspired development model, leveraging a seasoned leadership team with deep expertise in rare disease drug development and commercialization. Its strategy centers on advancing targeted therapies through late-stage clinical trials, supported by a strong financial position from prior capital raises, while navigating the high-risk, high-reward landscape of orphan drug development. Spruce has cultivated an award-winning corporate culture recognized for employee engagement and innovation.
View full company profile